<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025389</url>
  </required_header>
  <id_info>
    <org_study_id>12653A</org_study_id>
    <secondary_id>UCCRC-12653A</secondary_id>
    <secondary_id>NCI-2655</secondary_id>
    <secondary_id>OSU-0120</secondary_id>
    <nct_id>NCT00025389</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Study Of Neoadjuvant rhuMAb VEGF (Bevacizumab) In Combination With Paclitaxel And Carboplatin In Surgically Resectable Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy work&#xD;
      in different ways to stop tumor cells from dividing so they stop growing or die. Combining&#xD;
      monoclonal antibody therapy with chemotherapy before surgery may may shrink the tumor so that&#xD;
      it can be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is to see if bevacizumab, paclitaxel, and carboplatin given&#xD;
      before surgery work in treating patients who have stage IB, stage II, or stage IIIA non-small&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical complete and partial response rate in patients with stage IB, II,&#xD;
           or IIIA resectable non-small cell lung cancer treated with neoadjuvant bevacizumab,&#xD;
           paclitaxel, and carboplatin.&#xD;
&#xD;
        -  Determine the pathologic complete response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the ability to proceed with and complete a potentially curative resection in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety and toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive neoadjuvant bevacizumab IV over 60-90 minutes, paclitaxel IV over 3&#xD;
      hours, and carboplatin IV over 1 hour on day 1.&#xD;
&#xD;
      Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients undergo surgical resection within 4-6 weeks after completion of chemotherapy.&#xD;
&#xD;
      Patients are followed within 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-39 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (complete and partial responses by RECIST)</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer&#xD;
&#xD;
               -  Stage IB (T2, N0), II (T1 or T2, N1 or T3, N0), or IIIA (T3, N1)&#xD;
&#xD;
               -  Potentially resectable disease&#xD;
&#xD;
          -  No large central primary tumors in proximity to significant blood vessels&#xD;
&#xD;
          -  No bronchoscopically evident endobronchial tumors&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 12 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No history of an inherited bleeding disorder&#xD;
&#xD;
          -  No inherited predisposition to a hypercoagulable state&#xD;
&#xD;
          -  No clinically evident hypercoagulable state or bleeding diathesis&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  INR less than 1.5&#xD;
&#xD;
          -  PTT less than 36 seconds&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No nephrotic syndrome&#xD;
&#xD;
          -  Urine protein no greater than 0.5 g/24 hours&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No poorly controlled hypertension (greater than 150 mm Hg systolic and/or greater than&#xD;
             100 mm Hg diastolic) despite treatment&#xD;
&#xD;
          -  No uncompensated coronary artery disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No clinically significant or severe peripheral vascular disease&#xD;
&#xD;
          -  No inherited predisposition to thrombosis&#xD;
&#xD;
          -  No deep venous or arterial thrombosis&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris within the past 6 months&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No transient ischemic attack within the past 6 months&#xD;
&#xD;
          -  No cerebrovascular accident within the past 6 months&#xD;
&#xD;
          -  No other arterial thromboembolic event within the past 6 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No hemoptysis&#xD;
&#xD;
          -  No pulmonary embolism&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of allergic reactions to compounds of similar chemical or biologic&#xD;
             composition to study drugs&#xD;
&#xD;
          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant&#xD;
             human or humanized antibodies&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No uncontrolled concurrent illness&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  No requirement for full-dose anticoagulation or thrombolytic therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior biologic therapy for this cancer&#xD;
&#xD;
          -  No concurrent prophylactic growth factors (e.g., epoetin alfa, filgrastim [G-CSF], or&#xD;
             sargramostim [GM-CSF])&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for this cancer&#xD;
&#xD;
          -  Prior chemotherapy for another malignancy allowed provided the prior malignancy was&#xD;
             curatively treated and is currently controlled&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior endocrine therapy for this cancer&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy for this cancer&#xD;
&#xD;
          -  Prior radiotherapy for another malignancy allowed provided the prior malignancy was&#xD;
             curatively treated and is currently controlled&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior diagnostic bronchoscopy, mediastinoscopy, or CT-guided biopsy allowed&#xD;
&#xD;
          -  At least 28 days since prior major surgical procedure or open biopsy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer investigational or commercial agents or therapies&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  Concurrent low-dose warfarin for maintenence of preexisting, permanent, indwelling IV&#xD;
             catheters allowed provided INR less than 1.5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann M. Mauer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I non-small cell lung cancer</keyword>
  <keyword>stage II non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

